PEG-MGF
Get a source-linked, educational explanation from this profile.
Complete Research Guide
Open each section for the available evidence. Gaps are stated rather than inferred.
Overview
PEG-MGF is listed as recovery / mechano-growth factor analog.
- •Muscle repair (research)
Regulatory status: Research chemical — banned by WADA.
Structure & Properties
Compound: PEG-MGF; also known as Pegylated Mechano-Growth Factor, IGF-1Ec.
Pharmacologic class: Recovery / Mechano-Growth Factor Analog.
Known delivery routes: Subcutaneous, Intramuscular.
Sequence, molecular weight, salt form, and excipient details are formulation-specific and are not listed unless verified by a manufacturer or laboratory COA.
How It Works
PEGylated splice variant of IGF-1 (MGF / IGF-1Ec) — activates muscle satellite cells in response to mechanical loading; PEGylation extends half-life.
- •Satellite cell activation
- •Localized hypertrophy / repair
- •Potential tendon repair
Human Research
Evidence grade: Pre-clinical / Observational
Evidence is primarily preclinical or observational; human effectiveness and long-term safety are not established.
Laboratory Research
Pre-clinical only
Preclinical findings describe biological plausibility, not proven benefit in people. Animal and laboratory doses do not translate directly to human use.
Processing & Interactions
Timing and exposure
Post-workout only, injected locally near trained muscle groups. 1–3× per week on training days.
Potential interactions and combinations to avoid
- •Concurrent IGF-1 LR3 same site — additive mitogenic load
Absorption, half-life, metabolism, and clearance can vary by formulation and route. Use prescribing information when an approved product exists.
Safety & Precautions
Known or reported risks
- •Hypoglycemia
- •Theoretical tumor promotion
- •Injection-site reactions
Contraindications
- •Cancer history
- •Pregnancy
- •Active malignancy or history of hormone-sensitive tumor (GH/IGF-1 axis stimulation)
- •Active or untreated diabetic retinopathy
- •Insulin resistance, prediabetes, or poorly controlled type 2 diabetes
- •Untreated hypothyroidism or uncorrected adrenal insufficiency
- •Acromegaly, pituitary adenoma, or intracranial hypertension
- •Carpal tunnel syndrome, peripheral edema, or fluid-retentive heart failure
- •Critical illness after acute surgery, trauma, or respiratory failure
- •Severe obstructive sleep apnea (may worsen with soft-tissue growth)
- •Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- •Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- •Inability to maintain sterile technique or safe sharps disposal
- •Not FDA-approved for human therapeutic use — no verified purity, sterility, or potency standards
- •Immunocompromised or transplant patients (unverified sterility and immunogenicity risk)
- •Concurrent participation in drug-tested sport (WADA prohibited or non-cleared substance)
- •Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- •Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- •Children and adolescents with open growth plates (unless under specialist endocrine care)
- •Active or recently treated malignancy without oncology clearance
- •Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Unknown long-term toxicity should be assumed where controlled human data are limited. Seek urgent care for a severe or unexpected reaction.
Administration & Studied Formulations
Reference range: 100–200 mcg, 2–3×/week (anecdotal)
Frequency: Post-workout / multiple weekly
Cycling: 4–8 week cycles in user protocols.
Local Injection
Post-workout, near trained muscle.
29–30G × 1/2" insulin syringe. SubQ directly over the target muscle within 30 min of training. 1–3× / week.
Dosing information is educational context, not a personal recommendation. Approved products must follow their label and prescriber instructions.
Applications & Related Therapies
Potentially complementary measures
- •IGF-1 LR3 on alternate days
- •GH secretagogue stacks
Clinical use should account for diagnosis, approved alternatives, nutrition, activity, sleep, rehabilitation, current medicines, and appropriate monitoring.
Cases, Considerations & Ethics
Decision framework: establish the clinical goal, confirm evidence quality and legal status, screen contraindications and interactions, compare approved alternatives, define monitoring and stopping criteria, and use shared decision-making with a licensed clinician.
Case evidence: individual reports cannot establish safety or effectiveness and should not outweigh controlled trials.
Ethics: informed consent should distinguish established care from experimental use, disclose uncertainty and cost, avoid overstated claims, and never substitute research products for medically necessary care.
What is PEG-MGF?
In plain words
PEG-MGF is a lab-made version of a peptide linked to the muscle’s response to physical stress. An attached chemical chain is intended to slow how quickly the body clears it. Researchers study it for muscle repair, but reliable human evidence of benefit is lacking. Human safety is poorly understood, with concerns including low blood sugar, injection-site reactions, and a theoretical risk of promoting tumor growth.
Technical definition
PEG-MGF is an experimental polyethylene glycol (PEG)–conjugated peptide modeled on the E-domain of mechano-growth factor, an IGF-1 splice variant known as IGF-1Ec, rather than the complete IGF-1Ec molecule. Its proposed effects on muscle satellite cells involved in repair remain primarily preclinical, its specific receptor is not established, and PEGylation is intended to slow clearance. It is not FDA-approved and is prohibited by the World Anti-Doping Agency (WADA).
Function
Dosing
Recommended Time of Day
Post-workout on training days — 2–3× weekly.
See “Timing & Interactions” below for full fasted/fed circumstances, what to avoid combining, and what pairs well.
Administration & Technique
Injection & Application Sites
- Over the target / injured muscle — SubQ directly above the trained or injured muscle. Never intra-articular without imaging.
Diagram is a general illustration, not a medical instruction. Rotate sites every injection, keep 1 in (2.5 cm) between recent sites, and avoid scars, moles, bruises and the navel area.
Cycling
4–8 week cycles in user protocols.
Timing & Interactions
- ·Concurrent IGF-1 LR3 same site — additive mitogenic load
- ·IGF-1 LR3 on alternate days
- ·GH secretagogue stacks
Storage & Reconstitution
Reconstitution Calculator
1 mL = 100 units on a standard U-100 insulin syringe. Draw to the nearest 0.5 unit and confirm dosing with a clinician before injection.
Your Notes
Sign in to save personal notes on PEG-MGF and sync them to Vial Lab.
Benefits
- ·Satellite cell activation
- ·Localized hypertrophy / repair
- ·Potential tendon repair
Risks
- ·Hypoglycemia
- ·Theoretical tumor promotion
- ·Injection-site reactions
Contraindications
- ·Cancer history
- ·Pregnancy
- ·Active malignancy or history of hormone-sensitive tumor (GH/IGF-1 axis stimulation)
- ·Active or untreated diabetic retinopathy
- ·Insulin resistance, prediabetes, or poorly controlled type 2 diabetes
- ·Untreated hypothyroidism or uncorrected adrenal insufficiency
- ·Acromegaly, pituitary adenoma, or intracranial hypertension
- ·Carpal tunnel syndrome, peripheral edema, or fluid-retentive heart failure
- ·Critical illness after acute surgery, trauma, or respiratory failure
- ·Severe obstructive sleep apnea (may worsen with soft-tissue growth)
- ·Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- ·Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- ·Inability to maintain sterile technique or safe sharps disposal
- ·Not FDA-approved for human therapeutic use — no verified purity, sterility, or potency standards
- ·Immunocompromised or transplant patients (unverified sterility and immunogenicity risk)
- ·Concurrent participation in drug-tested sport (WADA prohibited or non-cleared substance)
- ·Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- ·Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- ·Children and adolescents with open growth plates (unless under specialist endocrine care)
- ·Active or recently treated malignancy without oncology clearance
- ·Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Regulatory
Research chemical — banned by WADA
Veterinary Use (Pets)
Occasional use in equine sports medicine for post-injury local hypertrophy.